Related Experiment Videos
Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia
Objective:
to investigate the epidemiology of infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia (VAP).
Design:
prospective clinical study.
Setting:
a medical-surgical ICU in a university hospital.
Patients:
we followed-up 568 mechanically ventilated patients and 83 episodes of VAP with etiologic diagnosis in 72 patients were retained for analysis.
Results:
Ps. aeruginosa was isolated in 22 (26.5%) episodes in 18 patients. Of these episodes 7 were directly responsible for death. Using logistic regression analysis, the risk of VAP due to Ps. aeruginosa was increased in patients with chronic obstructive pulmonary disease (relative risk (RR) = 29.9, 95% confidence interval (CI) = 4.86-184.53), a mechanical ventilation period longer than 8 days (RR = 8.1, 95% CI = 1.01-65.40) and prior use of antibiotics (RR = 5.5, 95% CI = 0.88-35.01).
Conclusions:
patients with VAP and these factors have a greater risk of infection by Ps. aeruginosa and empirical therapy for these episodes should include anti-pseudomonal activity until etiologic diagnosis is established.
Insights
Pseudomonas aeruginosa (Ps. aeruginosa) caused 26.5% of ventilator-associated pneumonia (VAP) cases. Risk factors include COPD, prolonged ventilation, and prior antibiotic use, necessitating early anti-pseudomonal therapy.
Area of Science:
- Critical Care Medicine
- Infectious Diseases Epidemiology
- Respiratory Medicine
Background:
- Ventilator-associated pneumonia (VAP) is a significant hospital-acquired infection.
- Pseudomonas aeruginosa is a common pathogen in VAP, associated with increased mortality.
- Understanding the epidemiology of Ps. aeruginosa VAP is crucial for effective treatment strategies.
Purpose of the Study:
- To investigate the epidemiology of Pseudomonas aeruginosa infections in patients with ventilator-associated pneumonia (VAP).
Main Methods:
- Prospective clinical study conducted in a university hospital's medical-surgical ICU.
- Follow-up of 568 mechanically ventilated patients.
- Analysis of 83 VAP episodes with etiologic diagnosis in 72 patients.
Main Results:
- Ps. aeruginosa was identified in 26.5% of VAP episodes (22/83), leading to death in 7 cases.
- Logistic regression identified chronic obstructive pulmonary disease (RR=29.9), ventilation >8 days (RR=8.1), and prior antibiotic use (RR=5.5) as risk factors for Ps. aeruginosa VAP.
- These factors significantly increased the risk of VAP caused by Ps. aeruginosa.
Conclusions:
- Patients with VAP and identified risk factors face a higher likelihood of Ps. aeruginosa infection.
- Empirical therapy for VAP in high-risk patients should include anti-pseudomonal agents pending etiologic diagnosis.
- Early consideration of Ps. aeruginosa is vital for appropriate VAP management.